S-Space College of Medicine/School of Medicine (의과대학/대학원) Orthopedic Surgery (정형외과학전공) Journal Papers (저널논문_정형외과학전공)
Expression of macrophage migration inhibitory factor relates to survival in high-grade osteosarcoma
- Han, Ilkyu; Lee, Mi Ra; Nam, Kwang Woo; Oh, Joo Han; Moon, Kyung Chul; Kim, Han-Soo
- Issue Date
- Lippincott, Williams & Wilkins
- Clin Orthop Relat Res. 2008;466(9):2107-2113
- Blotting, Western; Bone Neoplasms/*metabolism/*mortality; Cell Line, Tumor; Child; Child, Preschool; Immunohistochemistry; Intramolecular Oxidoreductases/*metabolism; Macrophage Migration-Inhibitory Factors/*metabolism; Multivariate Analysis; Neoplasm Invasiveness; Neovascularization, Pathologic/metabolism; Osteosarcoma/*metabolism/*mortality; Prognosis; Survival Analysis; Vascular Endothelial Growth Factor A/metabolism
- Macrophage migration inhibitory factor (MIF), a proinflammatory cytokine, is implicated in many aspects of tumor progression, including cell proliferation, invasion, and angiogenesis. We asked if MIF expression predicts survival and if it is associated with angiogenesis and cell invasion in osteosarcoma. We performed immunohistochemistry for MIF expression in prechemotherapy biopsy specimens of 58 patients with osteosarcoma. To investigate the role of MIF in angiogenesis, microvessel density was measured and compared with MIF expression. We also treated osteosarcoma cell lines (U2-OS and MG63) with MIF and measured vascular endothelial growth factor, a potent proangiogenic factor, by enzyme-linked immunosorbent assay. To study the role of MIF in cell invasion, Boyden chamber assay was performed after knockdown of MIF by short interfering RNA. MIF independently predicted overall survival and metastasis-free survival. MIF expression correlated with microvessel density and induced a dose-dependent increase in vascular endothelial growth factor. Knockdown of MIF by short interfering RNA resulted in decreased cell invasion. These results suggest MIF could serve as a prognostic marker and a potential therapeutic target for osteosarcoma. Level of Evidence: Level II, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence.
- 1528-1132 (Electronic)
- Files in This Item: There are no files associated with this item.